Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $38.0833.

JANX has been the topic of several recent analyst reports. Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. JonesTrading dropped their target price on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Finally, Guggenheim reduced their target price on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, May 8th.

Janux Therapeutics Price Performance

JANX stock opened at $15.58 on Friday. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34. The company has a market capitalization of $950.07 million, a P/E ratio of -8.47 and a beta of 2.52. The firm’s fifty day simple moving average is $14.90 and its 200-day simple moving average is $14.37.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. As a group, sell-side analysts forecast that Janux Therapeutics will post -1.7 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In related news, VP Maria Dobek sold 2,038 shares of Janux Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at $457,265.90. The trade was a 5.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after purchasing an additional 1,962,486 shares during the period. Prosight Management LP increased its position in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after purchasing an additional 1,527,173 shares during the period. Wellington Management Group LLP grew its holdings in Janux Therapeutics by 129.5% during the fourth quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock worth $22,221,000 after acquiring an additional 908,582 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Janux Therapeutics in the 4th quarter valued at about $12,221,000. Finally, Alyeska Investment Group L.P. increased its holdings in Janux Therapeutics by 206.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,301,089 shares of the company’s stock valued at $17,955,000 after buying an additional 876,244 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.